Companies › Kedrion
2 active drug programs in 3 registered trials: 3 Phase 3; Neurology, Hematology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Kedrion IVIG 10% Intravenous immunoglobulin (polyclonal IgG) | – | Phase 3 | Primary Immunodeficiency Disease; Chronic Primary Immune Thrombocytopenia (ITP) | Dec 2026 |
| KIg10 (QIVIGY) Intravenous Human Immune Globulin 10% | – | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04944979 | Kedrion IVIG 10% | Phase 3 | Primary Immunodeficiency Disease | Immunology | Dec 2026 |
| NCT07059000 | Kedrion IVIG 10% | Phase 3 | Chronic Primary Immune Thrombocytopenia (ITP) | Hematology | Dec 2026 |
| NCT06752356 | KIg10 (QIVIGY) | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Neurology | Dec 2027 |
No annotated target.
–
Incepta Pharmaceuticals Longbio Pharma Sandoz Neurona Therapeutics Doron Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.